Skip to content
SPC Logo

Inactivated Influenza Vaccine (Split Virion) BP

Last Updated on eMC 15-Mar-2017 View changes  | Sanofi Pasteur Contact details

1. Name of the medicinal product

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP, suspension for injection in prefilled syringe.

Influenza vaccine (split virion, inactivated).

2. Qualitative and quantitative composition

Influenza virus (inactivated, split) of the following strains*:

• A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)

............................................................................................................................15 micrograms HA**

• A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)

............................................................................................................................15 micrograms HA**

• B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)

............................................................................................................................15 micrograms HA**

Per 0.5 ml dose

* propagated in fertilised hens' eggs from healthy chicken flocks

** haemagglutinin

This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2016/2017 season.

For the full list of excipients, see Section 6.1.

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP may contain traces of eggs, such as ovalbumin, and of neomycin, formaldehyde and octoxinol- 9, which are used during the manufacturing process (see Section 4.3).

3. Pharmaceutical form

Suspension for injection in prefilled syringe.

The vaccine, after shaking gently, is a slightly whitish and opalescent liquid.

4. Clinical particulars
4.1 Therapeutic indications

Prophylaxis of influenza.

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP is indicated in adults and children from 6 months of age.

The use of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP should be based on official recommendations.

4.2 Posology and method of administration

Posology

Adults: 0.5 ml.

Paediatric population

Children from 36 months onwards: 0.5 ml.

Children from 6 months to 35 months: 0.25 ml. Clinical data are limited. See Section 6.6 for more information on administration of 0.25 ml dose.

If this is required by national recommendations, 0.5 ml may be given.

For children less than 9 years who have not previously been vaccinated, a second dose should be given after an interval of at least 4 weeks.

Children less than 6 months: the safety and efficacy of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP in children less than 6 months have not been established. No data are available.

Method of administration

Immunisation should be carried out by intramuscular or deep subcutaneous injection.

For adults and children from 36 months of age: the preferred site for intramuscular injection is the deltoid muscle.

For children from 12 to 35 months of age: the preferred site for intramuscular injection is the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate).

For children from 6 to 11 months of age: the preferred site for intramuscular injection is the anterolateral aspect of the thigh.

Precautions to be taken before handling or administering the medicinal product

For instructions on preparation of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substances, to any of the excipients listed in Section 6.1 or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol-9.

Vaccination should be postponed in case of moderate or severe febrile disease or acute disease.

4.4 Special warnings and precautions for use

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP should under no circumstances be administered intravascularly.

As with other vaccines administered intramuscularly, the vaccine should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.

As with any vaccine, vaccination with INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP may not protect 100% of susceptible individuals.

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.

Interference with serological testing

See Section 4.5.

4.5 Interaction with other medicinal products and other forms of interaction

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP may be given at the same time as other vaccines. Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.

The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the false-positive ELISA test results. The transient false positive reactions could be due to the IgM response by the vaccine.

4.6 Fertility, pregnancy and lactation

Pregnancy

Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of inactivated influenza vaccines do not indicate any adverse foetal and maternal outcomes attributable to the vaccine.

Breastfeeding

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP may be used during breastfeeding.

Fertility

No fertility data are available.

4.7 Effects on ability to drive and use machines

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

a. Summary of the safety profile

In recent clinical trials approximately 10,000 individuals from 6 months of age received INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP.

Depending on immunization history and the age of the children, the dosage and the number of doses were different (see Paediatric population in subsection b. Tabulated list of adverse reactions).

Solicited reactions usually occurred within the first 3 days following INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP, resolved spontaneously within 1 to 3 days after onset. Most of the solicited adverse reactions were of mild to moderate intensity.

The most frequently reported solicited adverse reaction within 7 days following injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP was injection site pain in all population except in children from 6 to 35 months in whom irritability was the most frequently reported.

The most frequently reported solicited systemic adverse reaction within 7 days following injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP was headache in adults, elderly and children from 9 to 17 years and malaise in children from 3 to 8 years.

Solicited adverse reactions were generally less frequent in elderly than in adults.

b. Tabulated list of adverse reactions

The data below summarize the frequencies of the adverse reactions that were recorded following vaccination with INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP during clinical trials and worldwide post-marketing experience.

Adverse events are ranked under headings of frequency using the following convention:

Very common (≥1/10);

Common (≥1/100 to <1/10);

Uncommon (≥1/1,000 to <1/100);

Rare (≥1/10,000 to <1/1,000);

Very rare (<1/10,000),

Not known (cannot be estimated from available data).

Adult and elderly

The safety profile presented below is based on data from more than 4300 adults and 5000 elderly over 60 years of age.

ADVERSE REACTIONS

FREQUENCY

Blood and Lymphatic System Disorders

Lymphadenopathy (1)

Uncommon

Transient thrombocytopenia

Not known

Immune System Disorders

Allergic reactions such as: swelling face (6), urticaria (6), prurit, generalized prurit (6), erythema, generalized erythema (6), rash

Rare

Severe allergic reactions such as dyspnoea, angioedema, shock

Not known

Nervous System Disorders

Headache

Very common

Dizziness (3), somnolence (2)

Uncommon

Hypoaesthesia (2), paresthesia, neuralgia (5), brachial radiculitis (3)

Rare

Convulsions, neurological disorders, such as encephalomyelitis, neuritis, Guillain Barré syndrome

Not known

Vascular disorders

Vasculitis such as Henoch-Schonlein purpura, with transient renal involvement in certain cases

Not known

Gastrointestinal Disorders

Diarrhoea, nausea (2)

Uncommon

Skin and Subcutaneous System Disorders

Sweating increased

Common

Musculoskeletal and Connective Tissue Disorders

Myalgia

Very common

Arthralgia

Common

General Disorders and Administration Site Conditions

Injection site pain/tenderness, injection site erythema/redness, injection site oedema/swelling, injection site induration, malaise (4), asthenia (4), injection site pruritus (4)

Very common

Fever, shivering/rigors, injection site bruising/ecchymosis

Common

Flu-like illness (2), injection site warmth (2), injection site discomfort (2)

Uncommon

(1) Rare in elderly

(2) Reported during clinical trials in adults

(5) Not known in adults

(3) Reported during clinical trials in elderly

(4) Common in elderly

(6) Not known in elderly

Paediatric population

Depending on immunization history, children from 6 months to 8 years received one or two doses of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP. Children from 6 to 35 months received the 0.25 ml formulation, and children from 3 years of age received the 0.5 ml formulation.

•  Children/adolescents from 3 to 17 years:

The safety profile presented below is based on data from more than 300 children from 3 to 8 years and around 70 children/adolescents from 9 to 17 years of age.

In children from 3 to 8 years of age, the most frequently reported solicited reactions within 7 days following injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP were injection site pain/tenderness (56.3%), malaise (27.3%), myalgia (25.5%) and injection site erythema/redness (23.4%).

In children/adolescents from 9 to 17 years of age, the most frequently reported solicited reactions within 7 days following injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP were injection site pain/tenderness (54.5% to 70.6%), headache (22.4% to 23.6%), myalgia (12.7% to 17.6%) and injection site erythema/redness (5.5% to 17.6%).

The data below summarize the frequencies of the adverse reactions that were recorded in children/adolescents from 3 to 17 years following vaccination with INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP during clinical trials and worldwide post-marketing experience.

ADVERSE REACTIONS

FREQUENCY

Blood and Lymphatic System Disorders

Lymphadenopathy (5)

Uncommon

Transient thrombocytopenia

Not known

Immune System Disorders

Urticaria (5)

Uncommon

Allergic reactions such as pruritus, rash erythematous, dyspnoea, angioedema, shock

Not known

Nervous System Disorders

Headache

Very common

Dizziness (2)

Common

Neuralgia, paresthesia, convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome

Not known

Vascular disorders

Vasculitis such as Henoch-Schonlein purpura, with transient renal involvement in certain cases

Not known

Gastrointestinal Disorders

Diarrhoea (1)

Uncommon

Musculoskeletal and Connective Tissue Disorders

Myalgia

Very common

General Disorders and Administration Site Conditions

Injection site pain/tenderness, injection site erythema/redness, injection site oedema/swelling, injection site induration (3), malaise

Very common

Fever, shivering/rigors (4), injection site bruising/ecchymosis, injection site discomfort (2), injection site pruritus

Common

Injection site warmth (3), injection site haemorrhage (1)

Uncommon

(1) Reported during clinical trials in children from 3 to 8 years old

(2) Reported during clinical trials in children/adolescents from 9 to 17 years old

(3) Common in children/adolescents from 9 to 17 years old

(4) Very common in children/adolescents from 9 to 17 years old

(5) Not known in children/adolescents from 9 to 17 years old

•  Children from 6 to 35 months:

The safety profile presented below is based on data from around 50 children from 6 to 35 months of age.

In one clinical trial, the most frequently reported solicited reactions within 3 days following injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP were injection site pain (23.5%), irritability (23.5%), fever (20.6%) and abnormal crying (20.6%).

In another trial, the most frequently reported solicited reactions within 7 days following injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP were irritability (60%), fever (50%), decreased appetite (35%) and abnormal crying (30%).

The data below summarize the frequencies of the adverse reactions that were recorded in children from 6 to 35 months within 3 or 7 days following one or two 0.25 ml doses of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP during these two clinical trials and worldwide post-marketing experience:

ADVERSE REACTIONS

FREQUENCY

Blood and Lymphatic System Disorders

Transient thrombocytopenia, lymphadenopathy

Not known

Immune System Disorders

Urticaria

Not known

Allergic reactions such as pruritus, rash erythematous, dyspnoea, angioedema, shock

Not known

Metabolism and nutrition Disorders

Decreased appetite, anorexia (1)

Very common

Psychiatric Disorders

Crying abnormal, irritability

Very common

Insomnia (1)

Common

Nervous System Disorders

Drowsiness

Very common

Paresthesia, convulsions, neurological disorders such as encephalomyelitis

Not known

Vascular disorders

Vasculitis such as Henoch-Schonlein purpura, with transient renal involvement in certain cases

Not known

Gastrointestinal Disorders

Diarrhoea (1)

Very common

Vomiting

Common

General Disorders and Administration Site Conditions

Injection site pain/tenderness, injection site erythema/redness, injection site oedema/swelling, injection site induration, fever

Very common

Injection site pruritus (1), injection site bruising (1)

Common

(1) Reported within 3 days after injection of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP

c. Other special populations

Although only a limited number of subjects with co-morbidities were enrolled, studies conducted in renal transplant patients, asthmatic patients, or children from 6 months to 3 years of age with medical conditions being at especially high risk of developing serious flu-related complications showed no major differences in terms of safety profile of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP in these populations.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9 Overdose

Cases of administration of more than the recommended dose (overdose) have been reported with INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP. When adverse reactions were reported, the information was consistent with the known safety profile of INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) BP described in Section 4.8.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02

An antibody immune response is generally induced within 2 to 3 weeks. The duration of postvaccinal induced immunity varies but is usually 6-12 months.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Not applicable.

6. Pharmaceutical particulars
6.1 List of excipients

Buffer solution:

• Sodium chloride

• Potassium chloride

• Disodium phosphate dihydrate

• Potassium dihydrogen phosphate

• Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

1 year.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the syringe in the outer carton in order to protect from light.

6.5 Nature and contents of container

0.5 ml of suspension in prefilled syringe (type I glass) with attached needle, equipped with a plunger stopper (elastomer chlorobromobutyl or chlorobutyl or bromobutyl) – pack size of 1, 10, 20 or 50.

0.5 ml of suspension in prefilled syringe (type I glass) without needle, equipped with a plunger stopper (elastomer chlorobromobutyl or chlorobutyl or bromobutyl) – pack size of 1, 10, 20 or 50.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The vaccine should be allowed to reach room temperature before use.

Shake before use. Inspect visually prior to administration.

The vaccine should not be used if foreign particles are present in the suspension.

Instructions for administration of 0.25 ml in children from 6 months to 35 months

When one dose of 0.25 ml is indicated, in order to eliminate half of the volume of the 0.5 ml syringe, the syringe should be held in an upright position and the plunger stopper should be pushed until it reaches the fine black line printed on the syringe. The remaining volume of 0.25 ml should be injected. See also Section 4.2.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Sanofi Pasteur Europe

2 Avenue Pont Pasteur

69007 Lyon

FRANCE

Distributed in the UK by:

Sanofi

One Onslow Street

Guildford

Surrey

GU1 4YS

8. Marketing authorisation number(s)

PL 46602/0002

9. Date of first authorisation/renewal of the authorisation

First authorization: 20 March 1998

Renewal of authorization: 30 December 2007

10. Date of revision of the text

03 March 2017

Company contact details

Sanofi Pasteur

Company image
Address

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK

Fax

+44 (0)1483 535 432

Medical Information e-mail
Telephone

+44 (0)1483 505 515

Medical Information Direct Line

+44 (0)845 372 7101

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

influenza vaccine

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue